Evidence map›Paper›PMID 40184560›Full record

ArticleJCO clinical cancer informatics2025

Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool.

Gillian Gresham, Michael Luu, N Lynn Henry, Tyra Nguyen, Katherine Barnhill, Greg Yothers, Sungjin Kim, Andre Rogatko, Deanna J Attai, Mourad Tighiouart and 2 more

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Online support needs and preferences for survivors of testicular cancer: a qualitative descriptive study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gillian GreshamDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-7142-1230
Michael LuuDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-7968-7313
N Lynn HenryDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
Tyra NguyenDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Katherine BarnhillDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Greg YothersDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA.ORCID 0000-0002-7965-7333
Sungjin KimDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-1150-703X
Andre RogatkoDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-8935-8890
Deanna J AttaiDepartment of Surgery, University of California Los Angeles, Los Angeles, CA.ORCID 0000-0002-1893-1183
Mourad TighiouartDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-8021-5690
Ron D HaysDepartment of Medicine, University of California Los Angeles, Los Angeles, CA.ORCID 0000-0001-6697-907X
Patricia A GanzDepartment of Medicine, University of California Los Angeles, Los Angeles, CA.ORCID 0000-0002-1841-4143

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Elaina Harper · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
The paradoxical roles of beta hydroxy butyrate in the liver pro-metastatic nicheP01CA233452 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BHOWMICK, NEIL A., LU, SHELLY CHI-LOO · 2020 to 2024
$9.5M
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical TrialsU01CA232859 · NCI · CEDARS-SINAI MEDICAL CENTER · PI GANZ, PATRICIA A., TIGHIOUART, MOURAD · 2018 to 2023
$3.7M
NCATS NIH HHS UL1 TR001881NCI NIH HHS P01 CA233452NCI NIH HHS U01 CA232859NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

purposeEndocrine treatments for patients with hormone-sensitive breast cancer are associated with significant side effects that can negatively affect health-related quality of life and result in treatment discontinuation. The objective of this qualitative study was to obtain feedback from stakeholder clinicians and patients about an online interactive tool that was designed to provide information and visualizations of breast cancer symptoms.

methodsThe online Breast Cancer Symptom Explorer tool was developed to allow patients to visualize trajectories for common symptoms associated with tamoxifen and anastrozole using symptom data from the NSABP B35 breast cancer clinical trial. To refine the tool, virtual focus groups were conducted among oncology clinicians and women with a history of breast cancer who had received treatment with an aromatase inhibitor or tamoxifen, seeking feedback on the tool and its potential usefulness. Discussions took place using a secure web-conferencing platform following a semi-structured interview guide. Focus groups were audio-recorded, transcribed, and analyzed using reflexive thematic analysis.

resultsNine focus groups were conducted (n = 21 participants: eight clinicians and 13 patients). Key benefits and barriers to tool use emerged from the discussions. Both patients and oncologists valued the ability to engage with the tool and visualize symptoms over time. They indicated that ideal settings for its use would be at home before treatment initiation. Combinations of graphical representations with text were perceived to be most effective in communicating symptoms. Key barriers identified included concerns about accessibility to the tool and digital literacy, with recommendations to simplify the text and provide health literacy support to enhance its clinical utility in the future.

conclusionClinician and patient involvement was critical for refinement of the breast cancer symptom explorer and provided insights into its future use and evaluation of the tool in clinical decision making.

Indexed as

Breast NeoplasmsAdultAgedFemaleFocus GroupsHumansInternetMiddle AgedQualitative ResearchQuality of LifeTamoxifenTamoxifen

Identifiers

PMID40184560
PMCPMC12967228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.